Integrated Quantitative Investments LLC Invests $325,000 in CareDx, Inc (NASDAQ:CDNA)

Integrated Quantitative Investments LLC bought a new stake in shares of CareDx, Inc (NASDAQ:CDNA) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 15,162 shares of the company’s stock, valued at approximately $325,000.

Several other institutional investors also recently bought and sold shares of CDNA. Vanguard Group Inc. boosted its holdings in shares of CareDx by 7.1% during the 4th quarter. Vanguard Group Inc. now owns 4,859,732 shares of the company’s stock valued at $104,047,000 after purchasing an additional 323,554 shares during the last quarter. Geode Capital Management LLC grew its holdings in CareDx by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,234,263 shares of the company’s stock valued at $26,432,000 after buying an additional 6,539 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in CareDx by 25.6% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 875,197 shares of the company’s stock worth $18,738,000 after acquiring an additional 178,304 shares during the last quarter. FMR LLC raised its holdings in shares of CareDx by 802.4% during the 3rd quarter. FMR LLC now owns 625,550 shares of the company’s stock worth $19,533,000 after acquiring an additional 556,230 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of CareDx by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 511,922 shares of the company’s stock valued at $10,960,000 after acquiring an additional 12,442 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on CDNA shares. StockNews.com upgraded shares of CareDx from a “hold” rating to a “buy” rating in a research report on Wednesday, February 26th. Stephens restated an “overweight” rating and set a $40.00 target price on shares of CareDx in a research report on Thursday, February 27th. Wells Fargo & Company upgraded CareDx from an “underweight” rating to an “equal weight” rating and dropped their price target for the stock from $28.00 to $24.00 in a research report on Wednesday, January 15th. Finally, HC Wainwright decreased their price objective on CareDx from $26.00 to $25.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, CareDx currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.83.

CareDx Stock Performance

CDNA opened at $17.28 on Friday. The stock’s 50 day moving average price is $20.90 and its 200-day moving average price is $23.28. CareDx, Inc has a one year low of $7.42 and a one year high of $34.84. The stock has a market cap of $957.76 million, a price-to-earnings ratio of -6.40 and a beta of 2.17.

CareDx (NASDAQ:CDNA) last announced its quarterly earnings data on Wednesday, February 26th. The company reported $1.51 EPS for the quarter, beating the consensus estimate of $0.05 by $1.46. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The company had revenue of $86.58 million for the quarter, compared to the consensus estimate of $84.56 million. As a group, analysts predict that CareDx, Inc will post -0.9 earnings per share for the current fiscal year.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.